Treatment of poor-risk non seminomatous germ-cell tumors (NSGCT) adapted by tumor marker decline: A 7-year multicenter real-world experience. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor–Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas Testicular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results